Psoriasis and Pentoxifylline: A Clinical, Histopathologic, and Immunohistochemical Evaluation

Geraldo Magela Magalhães, Sueli Coelho da Silva Carneiro, Karla Peisino Do Amaral, Flávia de Freire Cassia, Jackson Machado‐Pinto, Tullia Cuzzi

SKINmed Dermatology for the Clinician · 2006 · 10 citations · 29 references

Concepts

Abstract

OBJECTIVE: The aim of this study was to examine the clinical and histopathologic effects of pentoxifylline on psoriasis, compared with placebo. METHODS: Sixty-one outpatients with active psoriasis were randomly assigned to either of 2 groups: one was given pentoxifylline 400 mg tid PO, and the other, placebo. Fifty-six patients concluded the study. They were evaluated clinically and by laboratory parameters before and after 8 weeks of treatment. Pretreatment and posttreatment biopsies were taken. Initial sections were stained with hematoxylin-eosin. Further cuts were immunostained for cytokeratins 10, 14, and 16. RESULTS: Clinical and histologic improvement did not show statistically significant differences between the groups. No laboratory abnormalities or serious reactions related to the drug were observed. CONCLUSIONS: No statistical difference was seen when the treatment group was compared with the control group. Pentoxifylline is a well tolerated and safe drug, but its efficacy in psoriasis appears to be limited.

References

29